Compagnie Lombard Odier SCmA’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-1,000
Closed -$18.5K 648
2023
Q3
$18.5K Hold
1,000
﹤0.01% 491
2023
Q2
$11.1K Hold
1,000
﹤0.01% 498
2023
Q1
$13.4K Hold
1,000
﹤0.01% 540
2022
Q4
$12K Hold
1,000
﹤0.01% 594
2022
Q3
$14K Hold
1,000
﹤0.01% 556
2022
Q2
$14K Hold
1,000
﹤0.01% 533
2022
Q1
$16K Hold
1,000
﹤0.01% 534
2021
Q4
$16K Hold
1,000
﹤0.01% 603
2021
Q3
$15K Hold
1,000
﹤0.01% 582
2021
Q2
$20K Hold
1,000
﹤0.01% 556
2021
Q1
$23K Hold
1,000
﹤0.01% 566
2020
Q4
$25K Hold
1,000
﹤0.01% 491
2020
Q3
$41K Hold
1,000
﹤0.01% 402
2020
Q2
$48K Hold
1,000
﹤0.01% 378
2020
Q1
$63K Hold
1,000
﹤0.01% 339
2019
Q4
$124K Hold
1,000
﹤0.01% 293
2019
Q3
$66K Hold
1,000
﹤0.01% 343
2019
Q2
$80K Buy
+1,000
New +$89.5K ﹤0.01% 330
2017
Q4
Sell
-1,549
Closed -$90K 730
2017
Q3
$90K Buy
+1,549
New +$167K ﹤0.01% 452
2017
Q2
Sell
-1,759
Closed -$199K 770
2017
Q1
$199K Buy
+1,759
New +$205K 0.01% 369
2016
Q3
Sell
-2,436
Closed -$348K 940
2016
Q2
$348K Sell
2,436
-1,151
-32% -$168K 0.01% 401
2016
Q1
$461K Buy
+3,587
New +$424K 0.01% 349
2015
Q2
Sell
-40
Closed -$11K 951
2015
Q1
$11K Hold
40
﹤0.01% 895
2014
Q4
$6K Buy
+40
New +$7.39K ﹤0.01% 734

Compagnie Lombard Odier SCmA's ICPT Position: Q4 2023 in Review

Compagnie Lombard Odier SCmA sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 1,000 shares — an estimated $18.5K sold.

Compagnie Lombard Odier SCmA first reported a position in ICPT in Q4 2014 and held it in 24 quarters. The position peaked at $461K in Q1 2016. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

  • Compagnie Lombard Odier SCmA reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 1,000 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $18.5K.
  • Compagnie Lombard Odier SCmA first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 24 quarters.
  • Compagnie Lombard Odier SCmA's Intercept Pharmaceuticals, Inc. position peaked at $461K in Q1 2016.
  • 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2023, filed 16 Jan 2024.